August 2012
-
Propeller Health has partnered with US pharmacy benefits manager Express Scripts to provide Propeller’s inhaler monitoring platform to asthma and COPD patients enrolled in Express Scripts’ Pulmonary Care Value Program. According to the companies, patients… Read more . . .
-
The European Commission has approved GSK’s marketing authorization application for Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol DPI for the treatment of COPD, the company said. The EMA Committee for Medicinal Products for Human Use (CHMP) had issued… Read more . . .
-
CDMO Pharmaterials, which offers a wide range of development and manufacturing services for inhaled drugs, has been acquired by Quotient Sciences, Quotient said. Pharmaterials was previously owned by PII, which acquired the company in 2008.… Read more . . .
-
Innovus Pharmaceuticals says that it has launched FlutiCare fluticasone propionate nasal spray over the counter in the US in independent pharmacies and through its own online sites, as well as through Amazon and Walmart online… Read more . . .
-
Theravance Biopharma and Mylan have submitted an NDA to the FDA for revefenacin inhalation solution (TD-4208) for the treatment of COPD, the companies said. Theravance and Mylan announced their partnership on the development of nebulized… Read more . . .
-
Copley Scientific has announced the availability of 2 new breath simulators, the BRS 2100 and BRS 3100, that can generate patient-derived breathing profiles for inhaler and nebulizer testing in addition to the pharmacopeoeial standard breathing… Read more . . .
-
Evoke Pharma has announced that has signed a 5-year agreement with CDMO Patheon for commercial manufacturing of Evoke’s Gimoti intranasal metoclopramide for the treatment of diabetic gastroparesis. Patheon was acquired by Thermo Fisher earlier this… Read more . . .
-
The Japan Patent Office has allowed JP Application No. 2014-515967 which covers Neurelis’ NRL-1 intranasal diazepam formulation, the company said. In January 2017, Neurelis received Fast Track designation from the US FDA for NRL-1, which… Read more . . .
-
Novoclem Therapeutics says that its BIOC51 inhaled antimicrobial has received Qualified Infectious Disease Product (QIDP) designation from the FDA. The company says that BIOC51 could be delivered as either a dry powder or as an… Read more . . .
-
In a series of tweets, H&T Presspart has announced the official opening of a new dose counter/dose indicator manufacturing line at its facility in Marsberg, Germany. In 2014, 3M Drug Delivery Systems announced that it… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland